Posts

Posted on

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of AgEagle Aerial Systems Inc. (UAVS) Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of AgEagle Aerial Systems Inc. (UAVS) Investors

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired AgEagle Aerial Systems Inc. (“AgEagle” or the “Company”) (NYSE: UAVS) securities between September 3, 2019 and February 18, 2021, inclusive (the “Class Period”). AgEagle investors have until April 27, 2021 to file a lead plaintiff motion.

If you suffered a loss on your AgEagle investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/ageagle-aerial-systems-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On February 18, 2021, Bonitas Research published a report alleging, among other things, that AgEagle “was a pump & dump scheme orchestrated by Alpha Capital Anstalt (‘Alpha Capital’), AgEagle founder and former chairman Bret Chilcott and other UAVS insiders to defraud US investors.” The report also alleged that “in April 2020 rumor of a partnership between Amazon . . . & AgEagle was started by a promotional video uploaded to AgEagle’s founder and former chairman Bret Chilcott’s daughter’s personal website and youtube account” but that “we have found no evidence of any ‘major e-commerce customer.’” In mid-2020, AgEagle received over $23 million in proceeds from registered direct offerings. Then, in fourth quarter 2020, an Amazon spokesperson stated that the company does not have any dealings with AgEagle whatsoever.

On this news, AgEagle’s share price fell $5.13, or 36.4%, to close at $8.96 per share on February 18, 2021, thereby injuring investors.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) AgEagle did not have a partnership with Amazon and in fact never had any relationship with Amazon; (2) rather than correct the public’s understanding about a partnership with Amazon, defendants were actively contributing to the rumor that AgEagle had a partnership with Amazon; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired AgEagle securities during the Class Period, you may move the Court no later than April 27, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles H. Linehan, 310-201-9150 or 888-773-9224

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

www.glancylaw.com

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement

VANCOUVER, Washington, March 03, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has filed a “universal shelf” registration statement on Form S-3 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) to replace its previous shelf registration originally filed with the SEC on February 23, 2018 and set to expire on March 7, 2021.

The new Registration Statement, once declared effective by the SEC, will maintain the registration of previously issued and unexercised warrants, and provide the Company with the flexibility to access capital markets in the future on a timely and cost-effective basis.

There are no immediate plans to offer securities under the Registration Statement. The Company has maintained an active shelf registration since 2016. The securities being registered under the S-3 may not be sold, nor may offers to buy be accepted, until the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under its securities laws. Any offering of the securities covered under the Registration Statement will be made solely by means of the prospectus included in the relevant registration statement and any applicable prospectus supplement issued with respect to any offering.

Forward-Looking Statements 

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict.  Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTS

Investors:

Michael Mulholland
Office: 360.980.8524, ext. 102
[email protected]



Posted on

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors

BENSALEM, Pa–(BUSINESS WIRE)–
Law Offices of Howard G. Smith announces an investigation on behalf of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) investors concerning the Company’s possible violations of federal securities laws.

Aquestive is a specialty pharmaceutical company. Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.

On December 2, 2019, Aquestive announced the completion of the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for Libervant Buccal Film for the management of seizure clusters.

On September 25, 2020, Aquestive announced receipt of a Complete Response Letter (“CRL”) from the FDA stating that the NDA would not be approved in its current form. According to the CRL, “in a study submitted by the Company with the NDA, certain weight groups showed a lower drug exposure level than desired.” The Company stated that it “intends to provide to the FDA additional information on PK modeling to demonstrate that dose adjustments will obtain the desired exposure levels.”

On this news, Aquestive’s stock price fell $2.64 per share, or approximately 35%, to close at $4.97 per share on September 28, 2020.

If you purchased Aquestive securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

[email protected]

www.howardsmithlaw.com

KEYWORDS: United States North America California Pennsylvania

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Posted on

TopBuild Acquires Ozark Foam

Residential and Light Commercial Spray Foam Insulation $7.7 Million Annual Revenue

DAYTONA BEACH, Fla., March 03, 2021 (GLOBE NEWSWIRE) — TopBuild Corp.(NYSE:BLD) a leading installer and distributor of insulation and building material products in the United States, has acquired Ozark Foam, a residential and light commercial insulation company that primarily installs spray foam insulation. Founded in 1995 and serving customers in Missouri, Arkansas and Oklahoma, Ozark Foam generated approximately $7.7 million in revenue in 2020.

Robert Buck, President and CEO of TopBuild noted, “Ozark Foam is a terrific addition to our TruTeam installation business with a strong customer base and an experienced team of installers. We are also pleased that the two former owners, Randi and Tami Williams, have joined the TopBuild team. They will continue to manage and help us grow this business.”

Year-to-date, TopBuild has completed two acquisitions which are expected to generate close to $66 million of annual revenue and has entered into an agreement for another acquisition which is expected to generate an additional $144 million of annual revenue.

About TopBuild
TopBuild Corp., a Fortune 1000 Company headquartered in Daytona Beach, Florida, is a leading installer and distributor of insulation and building material products to the U.S. construction industry. We provide insulation and building material services nationwide through TruTeam®, which has approximately 200 branches, and through Service Partners® which distributes insulation and building material products from over 75 branches. We leverage our national footprint to gain economies of scale while capitalizing on our local market presence to forge strong relationships with our customers. To learn more about TopBuild please visit our website at www.topbuild.com.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements may address, among other things, our expected financial and operational results and the related assumptions underlying our expected results. These forward-looking statements are distinguished by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the negative of these terms, and similar references to future periods.   These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements.  Our forward-looking statements contained herein speak only as of the date of this press release.  Factors or events that we cannot predict, including those described in the risk factors contained in our filings with the Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements.  Although TopBuild believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, the Company can give no assurance that its expectations will be achieved and it undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by applicable law.

Investor Relations and Media Contact

Tabitha Zane
[email protected] 
386-763-8801



Posted on

ROSEN, A RESPECTED LAW FIRM, Encourages 9F Inc. Investors With Large Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action – JFU

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of 9F Inc. (NASDAQ: JFU): (i) pursuant and/or traceable to the registration statement and related prospectus issued in connection with 9F’s August 14, 2019 initial public offering (the “IPO” or “Offering”); and/or (ii) between August 14, 2019 and September 29, 2020, both dates inclusive (the “Class Period”), of the important March 22, 2021 lead plaintiff deadline in the securities class action first filed by the firm.

SO WHAT: If you purchased 9F securities pursuant and/or traceable to the IPO or during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the 9F class action, go to http://www.rosenlegal.com/cases-register-2007.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The complaint alleges that the materials supporting the Offering, and defendants throughout the Class Period, made false and/or misleading statements and/or failed to disclose that: (1) the purported value and benefits of the Company’s financial institution partners and its tri-party cooperation business model did not in fact exist and/or were materially overstated, given that 9F and Property and Casualty Company Limited (“PICC”) had been engaged in an ongoing contractual dispute regarding payment of service fees under the Cooperation Agreement; (2) the collectability of service fees owed to 9F by PICC under the Cooperation Agreement was in doubt and at serious risk of non-payment; (3) there was a significant risk that PICC would no longer provide credit insurance and guarantee protection to investors and institutional funding partners; (4) as a result of the foregoing, 9F’s platform, business model, reputation and financial results had been materially impaired; and (5) as a result, defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the 9F class action, go to http://www.rosenlegal.com/cases-register-2007.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com



Posted on

James Burke Named President of the Community Financial Corporation, Community Bank of the Chesapeake Holding Company

WALDORF, Md., March 03, 2021 (GLOBE NEWSWIRE) — The Board of Directors of Community Financial Corporation (“TCFC” or the “Company”), the holding company of Community Bank of the Chesapeake (“CBTC” or the “Bank”), has named James M. Burke as President of the Company, effective February 25, 2021. Jimmy is a banking veteran and currently serves as President of Community Bank of the Chesapeake. William Pasenelli, who has served as CEO and President of the Company, will continue to serve as Chief Executive Officer of the Company.

Austin J. Slater, Chairman of the Board of Directors, said on the appointment: “Jimmy has a wealth of experience working in executive management roles and extensive knowledge of the banking industry. His expertise, leadership and business acumen have been instrumental in the continued growth of the Company and Bank. His appointment to President of the Company is well deserved and, joined by all Directors, I congratulate Jimmy and look forward to continued collaboration.”

James M. Burke is an experienced banker with over 20 years of experience. Jimmy joined the Bank in 2005 and currently serves as Executive Vice President of the Company and President of the Bank. Prior to being appointed to President of the Bank in 2016, he served as Executive Vice President, Chief Risk Officer. Mr. Burke received his Bachelor of Arts degree in Political Science from High Point College in High Point, North Carolina.

“I have worked along-side Jimmy for many years,” said William Pasenelli, Chief Executive Officer of the Company and Bank. “His leadership, commitment to our culture and the experience of our customers and emphasis on creating shareholder value has driven the organization forward the past several years. Jimmy is a proven leader and I look forward to continuing to work with him as we lead the Company and Bank to future growth. I congratulate Jimmy on his appointment.”

Headquartered in Waldorf, Maryland, Community Bank of the Chesapeake is a full-service commercial bank, with assets over $2.0 billion.  Through its 12 banking centers and four dedicated commercial lending centers, Community Bank of the Chesapeake offers a broad range of financial products and services to individuals and businesses.  Community Bank of the Chesapeake is a wholly owned subsidiary of The Community Financial Corporation (NASDAQ: TCFC). More information about Community Bank of the Chesapeake can be found at www.cbtc.com.

CONTACT:         
Diane Hicks
Senior Vice President
Director of Marketing and Communications
(240) 427-1047
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/499aa440-1d7c-4a77-bf07-8bf7b0850b19

 



Record Date

 

Payment Date

 

Total Distribution

Per Share

 

Return of Capital

3/24/2020

 

3/31/2020

 

$0.0950

 

$0.0950

5/22/2020

 

5/29/2020

 

$0.0950

 

$0.0950

8/21/2020

 

8/28/2020

 

$0.0950

 

$0.0950

11/20/2020

 

11/27/2020

 

$0.0950

 

$0.0950

 

 

 

 

$0.3800

 

$0.3800

Shareholders are advised to consult their tax advisor about the specific tax treatment of 2020 distributions.

About Clipper Realty Inc.

Clipper Realty Inc. (NYSE: CLPR) is a self-administered and self-managed real estate company that acquires, owns, manages, operates and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. For more information on the Company, please visit www.clipperrealty.com.

Michael Frenz

Chief Financial Officer

(718) 438-2804 x2274

M: (917) 576-7750

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Posted on

Lattice Biologics Ltd. Announces Resignation of Director

Lattice Biologics Ltd. Announces Resignation of Director

BELGRADE, Mont.–(BUSINESS WIRE)–Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces that Mr. Donald McInnes has resigned as a director of the Company, effective immediately, so that he can focus his efforts on other professional commitments.

Guy Cook, CEO of the Company, commented: “On behalf of everyone at Lattice, we would like to thank Donald for his contributions. Mr. McInnes has been a valued director since the inception of the public Company in 2016.”

About Lattice Biologics Ltd.:

Lattice Biologics is traded on the TSX-V under the symbol: LBL.

Lattice Biologics develops and manufactures biologic products to domestic and international markets. The Company’s products are used in a variety of surgical applications.

Lattice Biologics maintains its headquarters, laboratory and manufacturing facilities in Belgrade, Montana .The facility includes ISO Class 1000 and ISO Class 100 clean rooms, and specialized equipment capable of crafting traditional allografts and precision specialty allografts for various clinical applications. The Lattice Biologics team includes highly trained tissue bank specialists, surgical technicians, certified sterile processing and distribution technicians, and CNC operators who maintain the highest standards of aseptic technique throughout each step of the manufacturing process. From donor acceptance to the final packaging and distribution of finished allografts, Lattice is committed to maintaining the highest standards of allograft quality, innovation, and customer satisfaction.

Lattice Biologics maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement on Forward-Looking Information:

Certain information contained in this news release constitutes “forward-looking statements” within the meaning of the ‘safe harbour’ provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “planned”, “potential”, “future”, “expected”, “could”, “possible”, “goal”, “intends”, “will” or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company’s strategy, plans, or future financial performance, such as statements with respect to the Transaction, and other statements that express management’s expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.

United States Advisory: The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the U.S. Securities Act) unless an exemption from the registration requirements of the U.S. Securities Act is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

Subscribe to Lattice News Updates

Follow us on Twitter: @LatticeBio

Guy Cook, CEO

Lattice Biologics Ltd.

(TSX-V: LBL) (OTCBB: LBLTF)

512 E. Madison Ave. Suite#A1

Belgrade, MT 59714

480-563-0800 Office

[email protected]

www.LatticeBiologics.com

KEYWORDS: Montana United States North America Canada

INDUSTRY KEYWORDS: Communications Health Surgery General Health Public Relations/Investor Relations Biotechnology

MEDIA:

Posted on

Dawson Wealth Management Group Joins UBS in San Diego

Dawson Wealth Management Group Joins UBS in San Diego

SAN DIEGO–(BUSINESS WIRE)–
UBS Wealth Management USA today announced that the Dawson Wealth Management Group joined the firm in San Diego, California. The team is led by Financial Advisor Edward (“Ed”) Dawson and includes Associates Adrianne Hoy, Kyle Dawson, Patty Bribiesca and Katherine Tawoda. The team has significant experience developing planning-based strategies, which enable clients to understand their wealth and the impact it can have on their families and society.

“We’re pleased to welcome the Dawson Wealth Management Group to UBS,” said Scott Hollaender, Downtown San Diego Branch Manager at UBS Wealth Management USA. “As a firm, we aim to help our clients achieve their goals and create a better world for the next generation. We know the team shares this philosophy and we look forward to seeing what they accomplish at UBS and how they go the extra mile to meet their clients’ needs.”

Ed Dawson, CFP®, CIMA® has spent over 30 years in the financial services industry and joins UBS as a Managing Director. His extensive experience handling the assets of high-net-worth clients throughout major market shifts enables him to structure balanced portfolios that address specific financial goals. An honors graduate of San Diego State University (SDSU), Ed also earned a Certified Investment Management Analyst (CIMA®) designation from the Wharton School of Business at the University of Pennsylvania. He works with several charitable organizations, including the YMCA and various Autism support groups.

Kyle Dawson, Ed’s son, joins UBS as a Financial Advisor. Kyle chose to follow in his father’s footsteps after graduating from the University of Miami. He spent seven years in sales and marketing roles prior to joining UBS. Kyle holds FINRA Series 7 and 66 registrations and is in the process of achieving the Certified Financial Planner® designation.

Adrianne Hoy joins UBS as a Senior Wealth Strategy Associate. Adrianne has more than 15 years of experience in customizing financial advice to meet the needs of her clients. She holds FINRA Series 7 and Series 66 registrations, as well as a California insurance license. Adrianne graduated with a Bachelor’s degree from SDSU and, prior to entering the financial services industry, taught science to students in San Diego County. She volunteers as a Court-Appointed Special Advocate with the charitable organization Voices for Children.

Patty Bribiesca joins UBS as a Senior Wealth Strategy Associate. Patty worked as a financial consultant for over 20 years, working closely with clients to develop personalized investment plans focused on real-life goals and dreams. She earned her Bachelor’s degree from Arizona State University and has completed advanced studies, earning the Accredited Wealth Management Advisor℠ designation through the College for Financial Planning. Patty holds FINRA Series 7, 66, 3, 9 and 10 registrations, as well as a California insurance license. She is committed to making a difference in the personal and professional lives of current and future generations of Latinas as the founder and circle leader of Lean In Latinas San Diego.

Katherine Tawoda joins UBS as a Senior Registered Client Service Associate. Katherine has over 17 years of experience in the financial services industry, having started her career as a bank teller upon earning an Associate’s Degree from Mesa College. She holds FINRA Series 7, 63, 65 registrations and a California insurance license. Katherine is committed to her local community, having lived in San Diego since she was 12, and often volunteers with organizations such as the Challenged Athletes Foundation, San Diego CoastKeeper, Father Joe’s Village, and Armed Services YMCA.

Notes to Editors

About UBS Global Wealth Management

As the world’s largest wealth manager, UBS Global Wealth Management provides comprehensive advice, solutions and services to wealthy families and individuals around the world. Clients who work with UBS benefit from a fully integrated set of wealth management capabilities and expertise, including wealth planning, investment management, capital markets, banking, lending and institutional and corporate financial advice.

https://www.ubs.com

© UBS 2021. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS.

Media contact:

Beth Walsh

858-254-2845

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Finance Consulting Banking Professional Services Other Professional Services

MEDIA:

Logo
Logo
Posted on

Tower One Secures MLA With “WOM”- Novator Partners LLP

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) — TOWER ONE WIRELESS CORP. (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) provides update on new customer in Colombia.

“We are very happy to announce we are now part of a handful of tower companies selected by WOM a new carrier in Colombia. WOM currently has great ambitions for the Colombian market and is estimating over 8,000 sites will be required in short order. Currently we are finalizing the first stage of this relationship allowing access to our existing tower base and helping us increase the tenant ratios. As a second stage we will assist in the build out of additional sites across Colombia.” Alejandro Ochoa – CEO Tower One Wireless

About WOM (Novator Partners LLP)

The UK-based investment fund Novator, owner of Chilean operator WOM, has announced the acquisition of a controlling stake in Colombian mobile operator Avantel. Novator acquired Nextel Chile in 2015 from US parent company when it had only 200k subscribers and rebranded into WOM, building a dynamic organisation and instilling a challenger, customer centric-culture which has enabled the business to grow to serve over 6 million subscribers. WOM is Chile’s 4th mobile market entrant with over 20% market share. https://novator.co.uk/

About Tower One

Tower One’s principal business is to build, own and operate multi-tenant wireless telecommunications infrastructure (“towers”) in Latin America. Tower One leases space on its towers to mobile network operators. The Company is focused on the build to suit tower industry whereby a long-term lease is secured with a tenant prior to building a tower. The Company operates in the three largest Spanish speaking countries in Latin America (Colombia, Mexico and Argentina) with a combined population of approximately 220 million people.

Contact Information:
Corporate Communications
Tel: +1 917 546 3016
E-mail: [email protected]
Website: www.toweronewireless.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this news release.


FORWARD LOOKING STATEMENTS

Certain statements in this release are forward-looking statements, which include regulatory approvals and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s expectation of obtaining the acceptance of new towers by the Company’s customers. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific that contributes to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. Forward-looking statement are necessarily based upon a number of factors that, if untrue, could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements express or implied by such statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, the impact of the ongoing COVID-19 pandemic, present and future business strategies, the environment in which the Company will operate in the future, and other factors, many of which are beyond the control of the Company. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. The Company assumes no obligation to update any forward-looking statements or forward-looking information referenced herein, whether as a result of new information events or otherwise, except as required by applicable securities laws.